Results 61 to 70 of about 6,454 (219)

Evaluating Tirzepatide\u27s Therapeutic Potential in Mitigating Obesity-Associated Comorbidities [PDF]

Objective: The study aims to explore the therapeutic potential of dual GIP/GLP-1 agonist tirzepatide in managing obesity and its associated manifestations, including obstructive sleep apnea (OSA), hidradenitis suppurativa (HS), and obesity-associated ...
Bryan, Carina, Jones, Talaya, Kahook, Zaneh, Parmar, Mayur   +3 more
core   +1 more source

Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain [PDF]

Dual agonists targeting glucagon-like peptide-1 receptor (GLP1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) are breakthrough treatments for patients with type 2 diabetes and obesity.
Adriaenssens, Alice E., Armour, Sarah, Ast, Julia, Broichhagen, Johannes, Cyranka, Malgorzata, de Bray, Anne, Epanchintsev, Alexey, Figueredo Burgos, Natalie S., Gatin-Fraudet, Blaise, Hodson, David J., Huhn, Christiane, Jiang, Wanqing, Jones, Ben, Ladds, Graham, Miyazaki, Satsuki, Nasteska, Daniela, Nieves, Daniel J., Owen, Dylan M., Pearce, Abigail, Reimann, Frank, Roberts, Anna G., Roßmann, Kilian, Shilleh, Ali H., Soykan, Tolga, Tomlinson, Jeremy W., Tong, Jason, Trapp, Stefan, Trott, James P. P., Viloria, Katrina, Ämmälä, Carina   +29 more
core   +1 more source

GLP‐1 Receptor Agonists for Obstructive Sleep Apnea: An Otolaryngologist's Prescription?

The Laryngoscope, EarlyView.
Alina Zgardau, Ryan Chin Taw Cheong, Kenny Peter Pang, Brian W. Rotenberg   +3 more
wiley   +1 more source

Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This study aims to compare the risk of major adverse cardiovascular events (MACE) among United States individuals with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) treated with once‐weekly semaglutide vs. dulaglutide.
Xi Tan, Yuanjie Liang, Lin Xie, Joanna Harton, Cynthia Gutierrez, Chalak Muhammad, Caroline Swift, Adam de Havenon   +7 more
wiley   +1 more source

Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials [PDF]

Aims/hypothesis: We conducted a systematic review and network meta-analysis to compare the efficacy and safety of s.c. administered tirzepatide vs s.c. administered semaglutide for adults of both sexes with type 2 diabetes mellitus.
Avgerinos, Ioannis, Bekiari, Eleni, Kakaletsis, Nikolaos, Kakotrichi, Panagiota, Karagiannis, Thomas, Liakos, Aris, Malandris, Konstantinos, Stamati, Athina, Tsapas, Apostolos, Vasilakou, Despoina   +9 more
core   +2 more sources

The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes [PDF]

, 2020
Aim To better understand the marked decrease in serum triglycerides observed with tirzepatide in patients with type 2 diabetes, additional lipoprotein-related biomarkers were measured post hoc in available samples from the same study.
Amir Nikooienejad, Axel Haupt, Borén J, Borén J, Chen M, Deborah A. Robins, Giacomo Ruotolo, Jeffrey S. Riesmeyer, Jonathan M. Wilson, Kamagate A, Karlson BW, Kevin L. Duffin, Marja‐Riitta Taskinen, Rizzo M, Taskinen MR, Taskinen MR, Thomas MK, Ussher JR, William C. Roell, Xiao C   +19 more
core   +1 more source

Effectiveness and adherence in a tirzepatide‐supported digital weight‐loss programme in Australia: A real‐world observational study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Obesity is a growing global health crisis; pharmacotherapies such as tirzepatide combined with multidisciplinary lifestyle support have shown promise but real‐world evidence in digital weight‐loss services (DWLSs) is limited. This retrospective study evaluated 6‐ and 12‐month weight loss, adherence and predictors of outcomes in an ...
Louis Talay, Jason Hom, Tamara Scott, Neera Ahuja   +3 more
wiley   +1 more source

The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials

Pharmaceuticals
Background: Obesity and type 2 diabetes (T2D) are major public health concerns. Tirzepatide has shown promise in recent clinical trials. This systematic review and meta-analysis aim to evaluate the efficacy and safety of tirzepatide in adults with ...
Ligang Liu, Hekai Shi, Merilyn Xie, Yuxiao Sun, Milap C. Nahata   +4 more
doaj   +1 more source

Evaluating the Therapeutic Potential of Tirzepatide in Liver Diseases: A Comprehensive Review [PDF]

Objective: This review examines tirzepatide, a GLP-1 agonist, to treat liver diseases like nonalcoholic fatty liver disease (NAFLD) and metabolic-associated steatohepatitis (MASH).
Bryan, Carina, Jones, Talaya, Kahook, Zaneh, Parmar, Mayur S   +3 more
core   +1 more source

Use of Tirzepatide in adults with type 2 diabetes mellitus: scientifc evidence and practical aspects [PDF]

Tirzepatide is a novel antidiabetic medication a single-molecule, agonist to the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. It is approved in the USA and EU for the treatment of type 2 diabetes mellitus (T2DM) and
Bellido-Guerrero, D., Botella-Serrano, M., Causanilles, A., Delgado, E., Fajardo-Montañana, C., Jódar‑Gimeno, E., Mezquita-Raya, P., Morales-Portillo, C., Romera, I, Romera, I., Rubio‑de Santos, M., Soto-González, A., Tofé-Povedano, S., Vázquez Salví, Luis Alberto   +13 more
core   +1 more source